R Gätje

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

G. von Minckwitz, T. Karn, S. Loibl, 2007, Breast.

Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive Signatures

T. Karn, S. Loibl, A. Ahr, 2005, Zentralblatt fur Gynakologie.